B2M and non-small cell lung carcinoma: McGranahan et al found that HLA mutations are a pervasive immune escape mechanism in NSCLC progression in 2017.[87] The inactivation of B2M genes leads to reduced or missing expression of major histocompatibility complex Class I molecules, making them unrecognized by CD8 T cells the main cause of immunotherapy resistance in NSCLC.[88]